Javier Castañeda

2.4k total citations · 2 hit papers
56 papers, 1.6k citations indexed

About

Javier Castañeda is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Javier Castañeda has authored 56 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Surgery and 23 papers in Genetics. Recurrent topics in Javier Castañeda's work include Diabetes Management and Research (36 papers), Pancreatic function and diabetes (23 papers) and Diabetes Treatment and Management (19 papers). Javier Castañeda is often cited by papers focused on Diabetes Management and Research (36 papers), Pancreatic function and diabetes (23 papers) and Diabetes Treatment and Management (19 papers). Javier Castañeda collaborates with scholars based in Switzerland, Netherlands and United States. Javier Castañeda's co-authors include Ohad Cohen, Arcelia Arrieta, Tadej Battelino, John Shin, Julien Da Silva, Ignacio Conget, Yves Reznik, C. González, Ronnie Aronson and Tim van den Heuvel and has published in prestigious journals such as The Lancet, Diabetes Care and The Journal of Physiology.

In The Last Decade

Javier Castañeda

51 papers receiving 1.6k citations

Hit Papers

Real-World Performance of the MiniMed™ 780G System: First... 2021 2026 2022 2024 2021 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
    2021 157 citations Julien Da Silva, Giuseppe Lepore et al. Diabetes Technology & Therapeutics profile →
  2. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
    2022 107 citations Pratik Choudhary, Charles Thivolet et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Castañeda Switzerland 21 1.2k 790 734 190 154 56 1.6k
Iain Cranston United Kingdom 15 903 0.8× 495 0.6× 466 0.6× 56 0.3× 185 1.2× 33 1.3k
Linford J.B. Briant United Kingdom 16 467 0.4× 534 0.7× 261 0.4× 167 0.9× 145 0.9× 26 1.0k
M. A. Burnett United Kingdom 14 843 0.7× 663 0.8× 324 0.4× 91 0.5× 239 1.6× 21 1.4k
Larry A. Fox United States 21 1.2k 1.0× 855 1.1× 720 1.0× 8 0.0× 93 0.6× 47 1.6k
Craig Kollman United States 27 1.8k 1.5× 1.4k 1.7× 1.2k 1.7× 12 0.1× 112 0.7× 49 2.3k
Yoon Hi Cho Australia 16 438 0.4× 218 0.3× 249 0.3× 21 0.1× 121 0.8× 34 796
Philippe Klee Switzerland 15 155 0.1× 270 0.3× 126 0.2× 48 0.3× 74 0.5× 26 589
Evangelos Bozas Greece 15 180 0.2× 164 0.2× 222 0.3× 14 0.1× 51 0.3× 31 728
Lucas C. González-Matías Spain 17 389 0.3× 179 0.2× 61 0.1× 183 1.0× 194 1.3× 21 860
Luis Rodrigo Cataldo Chile 16 115 0.1× 149 0.2× 131 0.2× 62 0.3× 156 1.0× 45 702

Countries citing papers authored by Javier Castañeda

Since Specialization
Citations

This map shows the geographic impact of Javier Castañeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Castañeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Castañeda more than expected).

Fields of papers citing papers by Javier Castañeda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Castañeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Castañeda. The network helps show where Javier Castañeda may publish in the future.

Co-authorship network of co-authors of Javier Castañeda

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Castañeda. A scholar is included among the top collaborators of Javier Castañeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Castañeda. Javier Castañeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alam, Amit, et al.. (2025). COPD and Secondary Pulmonary Hypertension: Shifting Mortality Trends, Geographic Disparities, and Racial/Ethnic Variations in the U.S.. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A4242–A4242.
2.
Heller, Simon, David N. O’Neal, Johan Jendle, et al.. (2025). MiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets. Diabetes Obesity and Metabolism. 27(4). 2242–2250. 4 indexed citations
3.
Arrieta, Arcelia, Javier Castañeda, Michaël Joubert, et al.. (2025). Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26 427 Users. Journal of Diabetes Science and Technology. 580927589–580927589.
4.
5.
Heuvel, Tim van den, Javier Castañeda, Arcelia Arrieta, et al.. (2024). Generating real‐world evidence on diabetes technology using the CareLink Personal data management system. Diabetes Obesity and Metabolism. 26(11). 4846–4853. 3 indexed citations
6.
Matejko, Bartłomiej, Tim van den Heuvel, Javier Castañeda, et al.. (2024). Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort. Diabetes Research and Clinical Practice. 216. 111832–111832. 3 indexed citations
7.
Castañeda, Javier, Bastiaan E. de Galan, Sander M. J. van Kuijk, et al.. (2024). The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery. Diabetes Obesity and Metabolism. 26(12). 5836–5844. 2 indexed citations
8.
Choudhary, Pratik, et al.. (2024). Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technology & Therapeutics. 26(3_suppl). 32–37. 36 indexed citations
9.
Aktürk, Halis Kaan, Tadej Battelino, Javier Castañeda, et al.. (2024). Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 26(3_suppl). 102–106. 13 indexed citations
10.
Castañeda, Javier, Pratik Choudhary, Charles Thivolet, et al.. (2023). Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes Obesity and Metabolism. 25(11). 3212–3222. 11 indexed citations
11.
Castañeda, Javier, Arcelia Arrieta, Tim van den Heuvel, Tadej Battelino, & Ohad Cohen. (2023). Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System. Diabetes Care. 47(5). 790–797. 50 indexed citations
12.
Choudhary, Pratik, Charles Thivolet, Simona de Portu, et al.. (2022). Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. The Lancet Diabetes & Endocrinology. 10(10). 720–731. 107 indexed citations breakdown →
13.
Silva, Julien Da, Giuseppe Lepore, Tadej Battelino, et al.. (2021). Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users. Diabetes Technology & Therapeutics. 24(2). 113–119. 157 indexed citations breakdown →
14.
Castañeda, Javier, Harold de Valk, Pratik Choudhary, et al.. (2020). Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial. Diabetes Technology & Therapeutics. 22(9). 681–685. 1 indexed citations
15.
Valk, Harold W. de, Sandrine Lablanche, Emanuele Bosi, et al.. (2018). Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. Diabetes Technology & Therapeutics. 20(11). 758–766. 6 indexed citations
16.
Prieto‐Lloret, Jesús, María José Ramírez-Bajo, Elena Olea, et al.. (2015). Hypoxic pulmonary vasoconstriction, carotid body function and erythropoietin production in adult rats perinatally exposed to hyperoxia. The Journal of Physiology. 593(11). 2459–2477. 8 indexed citations
17.
Aronson, Ronnie, Ohad Cohen, Ignacio Conget, et al.. (2014). OpT2mise: A Randomized Controlled Trial to Compare Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 2 Diabetes—Research Design and Methods. Diabetes Technology & Therapeutics. 16(7). 414–420. 14 indexed citations
18.
Hommel, E., Birthe Susanne Olsen, Tadej Battelino, et al.. (2014). Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. Acta Diabetologica. 51(5). 845–851. 84 indexed citations
19.
Obeso, Ana, et al.. (2010). Moderate ethanol ingestion, redox status, and cardiovascular system in the rat. Alcohol. 45(4). 381–391. 10 indexed citations
20.
González‐Martín, Carmen, et al.. (2009). Effects of Intermittent Hypoxia on Blood Gases Plasma Catecholamine and Blood Pressure. Advances in experimental medicine and biology. 648. 319–328. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iain Cranston Breakdown of academic impact, for papers by Linford J.B. Briant Breakdown of academic impact, for papers by M. A. Burnett Breakdown of academic impact, for papers by Larry A. Fox Breakdown of academic impact, for papers by Craig Kollman Breakdown of academic impact, for papers by Yoon Hi Cho Breakdown of academic impact, for papers by Philippe Klee Breakdown of academic impact, for papers by Evangelos Bozas Breakdown of academic impact, for papers by Lucas C. González-Matías Breakdown of academic impact, for papers by Luis Rodrigo Cataldo
Rankless by CCL
2026